Evidence map›Paper›PMID 35257310›Full record

ArticleMolecular biotechnology2022

MiR-221-3p Facilitates Thyroid Cancer Cell Proliferation and Inhibit Apoptosis by Targeting FOXP2 Through Hedgehog Pathway.

Wang Chang, Qing Chang, Haodong Lu, Yanbing Li, Chunyou Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. FOXP2 mediates ZSCAN18 transcriptional activation to inhibit oral squamous cell carcinoma progression by blocking Hedgehog signaling.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Article
  5. Tubular FoxP2 and Kidney Fibrosis.Journal of the American Society of Nephrology : JASN · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wang ChangDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, 27# Wenhua Road, Tangshan, 063000, Hebei Province, China.
Qing ChangDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, 27# Wenhua Road, Tangshan, 063000, Hebei Province, China.
Haodong LuDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, 27# Wenhua Road, Tangshan, 063000, Hebei Province, China.
Yanbing LiDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, 27# Wenhua Road, Tangshan, 063000, Hebei Province, China.
Chunyou ChenDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, 27# Wenhua Road, Tangshan, 063000, Hebei Province, China. chunyouccchen@163.com.ORCID http://orcid.org/0000-0002-7689-8721
Tangshan Gongren Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer (TC) is most often found in the endocrine system, the incidence of which has been on a continuous increase in recent years. For a better treatment of it, it becomes a pressing matter to further delve into the mechanism of TC onset and progression. FOXP2 is lowly expressed in diverse cancer, which has a deep connection with malignant progression of tumors. However, in TC, studies about this gene are exceedingly limited. In this study, FOXP2 was discovered to be lowly expressed in TC tissues based on the analysis of TCGA database. This finding was further confirmed by the qRT-PCR that FOXP2 was lowly expressed in TC cell lines. The results of a series of cell function assays demonstrated that overexpressed FOXP2 could hamper TC cell proliferation and stemness, facilitate apoptosis, and arrest the cell cycle. For a deep exploration of its mechanism, we mined its upstream factor miR-221-3p with the aid of starBase and mirDIP databases. The dual-luciferase reporter assay was employed to verify the binding relationship between miR-221-3p and FOXP2. Besides, we also discovered the HEDGEHOG pathway existing downstream of FOXP2 by gene set enrichment analysis. Based on these findings, we also performed a rescue experiment, the result of which indicated that the overexpression of FOXP2 was able to reverse the effects of overexpressed miR-221-3p in several cell activities including proliferation, sphere-formation, apoptosis, and cell cycle. Besides, it could also have an impact on the expression of HEDGEHOG pathway-related proteins influenced by overexpressed miR-221-3p. Our study provided the new insights into the mechanism by which miR-221-3p functions in the development of TC.

Indexed as

MicroRNAsSignal TransductionThyroid NeoplasmsApoptosisCell Line, TumorCell ProliferationForkhead Transcription FactorsHedgehog ProteinsHumansForkhead Transcription FactorsFOXP2 protein, humanHedgehog ProteinsMicroRNAsMIR221, humanApoptosisFOXP2miR-221-3pProliferationThyroid cancer

Identifiers

PMID35257310
OpenAlexW4221066541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.